R A'Hern

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management
    N Lynn Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan 48109 5419, USA
    Oncology (Williston Park) 22:1401-8. 2008
  2. pmc Predictors of recovery of ovarian function during aromatase inhibitor therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Ann Oncol 24:2011-6. 2013
  3. pmc Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Med Inn Bldg C450, Ann Arbor, MI 48109 5843, USA
    Breast Cancer Res Treat 138:807-16. 2013
  4. doi request reprint Cancer biomarkers
    N Lynn Henry
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 5843, USA
    Mol Oncol 6:140-6. 2012
  5. pmc Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
    N Lynn Henry
    University of MichiganComprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:936-42. 2012
  6. doi request reprint Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Cancer 117:5469-75. 2011
  7. pmc Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study
    N L Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, 300 North Ingalls, North Ingalls Building 3A04, Ann Arbor, MI 48109 5419, USA
    Br J Cancer 103:291-6. 2010
  8. pmc A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
    Cancer 116:4360-7. 2010
  9. pmc Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Br J Cancer 102:294-300. 2010
  10. ncbi request reprint Adjuvant systemic therapy for elderly women with breast cancer
    N Lynn Henry
    Department of Internal Medicine, University of Michigan, Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Womens Health (Lond Engl) 2:75-87. 2006

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management
    N Lynn Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Medical School, Ann Arbor, Michigan 48109 5419, USA
    Oncology (Williston Park) 22:1401-8. 2008
    ..Increased knowledge about the etiology and management of this clinically important toxicity could potentially improve patient adherence to AI therapy, thereby leading to a reduction in breast cancer recurrence and death...
  2. pmc Predictors of recovery of ovarian function during aromatase inhibitor therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Ann Oncol 24:2011-6. 2013
    ..We carried out a prospective registry trial to identify predictors of ovarian function recovery during AI therapy...
  3. pmc Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Med Inn Bldg C450, Ann Arbor, MI 48109 5843, USA
    Breast Cancer Res Treat 138:807-16. 2013
    ..An inherited variant potentially affecting estrogen signaling may be associated with exemestane-associated toxicity, which could partially account for intra-patient differences in AI tolerability. Validation of this finding is required...
  4. doi request reprint Cancer biomarkers
    N Lynn Henry
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 5843, USA
    Mol Oncol 6:140-6. 2012
    ..In this review we address key steps in the development of biomarkers, including ways to avoid introducing bias and guidelines to follow when reporting results of biomarker studies...
  5. pmc Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer
    N Lynn Henry
    University of MichiganComprehensive Cancer Center, Ann Arbor, MI, USA
    J Clin Oncol 30:936-42. 2012
    ..Predictors of treatment discontinuation are not clearly defined. It is unknown whether patients with intolerable toxicity from one AI are able to tolerate another...
  6. doi request reprint Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    Cancer 117:5469-75. 2011
    ..The authors investigated the hypothesis that duloxetine is efficacious for treatment of AI-associated musculoskeletal symptoms...
  7. pmc Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study
    N L Henry
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, 300 North Ingalls, North Ingalls Building 3A04, Ann Arbor, MI 48109 5419, USA
    Br J Cancer 103:291-6. 2010
    ..Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers...
  8. pmc A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5419, USA
    Cancer 116:4360-7. 2010
    ..Tendon sheath fluid and tenosynovial changes have been demonstrated by imaging symptomatic patients who were treated with AIs. The authors hypothesized that these abnormalities are correlated with AIMSS...
  9. pmc Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
    N L Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Br J Cancer 102:294-300. 2010
    ..We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone...
  10. ncbi request reprint Adjuvant systemic therapy for elderly women with breast cancer
    N Lynn Henry
    Department of Internal Medicine, University of Michigan, Comprehensive Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Womens Health (Lond Engl) 2:75-87. 2006
    ....
  11. pmc Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Breast Cancer Res Treat 117:571-5. 2009
    ..062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy...
  12. pmc Drug interactions and pharmacogenomics in the treatment of breast cancer and depression
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, 300 North Ingalls St, Bldg 3A04, Ann Arbor, MI 48109 5419, USA
    Am J Psychiatry 165:1251-5. 2008
  13. ncbi request reprint Use of gene-expression profiling to recommend adjuvant chemotherapy for breast cancer
    N Lynn Henry
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 5843, USA
    Oncology (Williston Park) 21:1301-9; discussion 1311, 1314, 1319. 2007
    ..Large, multinational clinical trials are currently ongoing to evaluate the use of two of the multiparameter assays, although it will be many years before oncologists can apply the results of these trials in the clinic...